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Abstract
Background: Severe anemia is a common side effect of Pegylated Interferon + Ribavirin (PR) and Telaprevir (TVR) in hepatitis
C virus (HCV) genotype 1 patients with advanced fibrosis or cirrhosis (F3–F4). Inosine triphosphatase (ITPA) genetic variants
are associated with RBV- induced anemia and dose reduction.
Aim: To test the association of ITPA polymorphisms rs1127354 and rs7270101 with hemoglobin (Hb) decline, need for RBV
dose reduction (RBV DR), erythropoietin (EPO) support and blood transfusions during the first 12 weeks of TVR triple
therapy.
Materials and Methods: 69 consecutive HCV-1 patients (mean age 57 years) with F3-F4 who received PR and TVR were
genotyped for ITPA polymorphisms rs1127354 and rs7270101. Estimated ITPA deficiency was graded on severity (0–3, no
deficiency/mild/moderate/severe).
Results: ITPA deficiency was absent in 48 patients (70%), mild in 12 (17%) and moderate in 9 patients (13%). Mean week
4 Hb decline was higher in non ITPA deficient patients (3,85 g/dL) than in mildly or moderately ITPA deficient patients
(3,07 g/dL and 1,67 g/dL, p,0.0001). Grade 3–4 anemia developed in 81% non ITPA deficient patients versus 67% mild
deficient and 55% moderate deficient patients (p = ns). Grade of ITPA deficiency was not associated with RbvDR (no
deficiency: 60%, mild: 58%, moderate: 67%; p = ns), EPO use (no deficiency: 65%, mild: 58%, moderate:56%; p = ns) or need
for blood transfusion (no deficiency: 27%, mild: 17%, moderate: 33%; p = ns).
Conclusions: In patients with F3–F4 chronic hepatitis C receiving TVR based therapy, ITPA genotype does not impact on the
management of early anemia.
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Introduction
The first generation inhibitors of the Hepatitis C virus (HCV)
NS3 protein, Telaprevir (TVR) and Boceprevir (BOC), when
combined with Pegylated Interferon and Ribavirin (PR) are the
standard of care regimen for patients with HCV-1 [1]. This triple
therapy regimen has provided an increase in achievable sustained
virological response (SVR) rates compared to PR both in
treatment naive patients, as well as in patients who have failed
to respond to a previous course of PR. Still in the most in need
group of patients, those with advanced fibrosis/cirrhosis, SVR
rates are still subpar, especially in the subgroup of those classified
as null-responders to the previous course of PR [2]. Moreover,
several real-life studies have shown that in patients with advanced
fibrosis/cirrhosis the side effect profile of triple therapy is especially
cumbersome in terms of anemia and infection rates, often leading
to premature treatment discontinuation or development of serious
adverse events (SAE) [3–4]. With regards to TVR, the interna-
tional early access program, enrolling more than 1600 patients
with advanced fibrosis/cirrhosis who received PR+TVR at
standard dose, demonstrated that on treatment anemia developing
in the first 12–16 weeks is the main clinical issue of this regimen
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[4]. Indeed anemia was the most common SAE and the most
frequent reason for treatment discontinuation, ultimately requiring
blood transfusions in 10% of the patients and Erythropoietin
support in nearly 20% of enrolled patients. This data is consistent
with other real-life studies of TVR, reporting anemia to be the
most frequent cause for SAE [5–6]. Baseline prediction of early
anemia to TVR based regimens in patients with advanced
fibrosis/cirrhosis is therefore of paramount importance as it may
allow individual counselling and timely interventions to correctly
manage this side effect.
For this reason we decided to study the role of single nucleotide
polymorphisms (SNPs) in the Inosine Triphosphatase (ITPA) gene
in determining PR+TVR early anemia in patients with HCV-1
advanced fibrosis/cirrhosis. The combination of the two ITPA
SNPs, rs1127354 and rs7270101, determines the relative deficien-
cy of the ITPA protein, which in turn has been associated with the
grade of anemia during PR therapy [7–8]. The explained
mechanism is that RBV-metabolites accumulate within erythro-
cytes depleting intracellular adenosine triphosphate (ATP) and
guanosine triphosphate (GTP), leading to membrane oxidative
stress and consequent haemolysis. The reduced ITPA activity
increases intracellular Inosine triphosphate (ITP) levels, allowing
ITP to substitute GTP in the generation of Adenosine mono-
phosphate (AMP), thus maintaining the activity of membrane
transporters and avoiding haemolysis of red cells.
However the clinical utility of ITPA SNPs in predicting anemia
severity in TVR based regimens to date is still relatively unknown,
as it has been studied mostly in patients of Asian ethnicity and
never in patients with advanced fibrosis/cirrhosis [9–10].
Patients and Methods
Patients
This retrospective cohort study was performed in all consecutive
HCV-1 patients with chronic hepatitis C genotype 1 and advanced
fibrosis who received TVR based therapy at the Liver Center of
the Ospedale Maggiore Policlinico in Milan and at the Hepatology
Unit of the San Giuseppe Hospital in Milan between January and
June 2013. All patients gave their written consent for treatment
and genotyping of ITPA polymorphisms rs1127354 and
rs7270101.
Chronic hepatitis C was defined by at least one year serum
positivity for serum HCV-RNA assessed by quantitative RT-PCR
assay with detection limit of 12 IU/ml. Advanced Fibrosis was
defined by a liver biopsy performed before treatment, consistent
with chronic hepatitis C and F3–F4 according to the METAVIR
score, or by a transient elastography value $9.5 KPa. Fibroscan
cut-off to diagnose bridging fibrosis and cirrhosis was $9.5 KPa
and $12.5 KPa, respectively.
Exclusion criteria were: 1) co-infection with hepatitis B virus
(HBV) or human immunodeficiency virus (HIV), 2) decompen-
sated liver disease, 3) drug dependence or .40 g/day alcohol
intake, 4) general contraindication to PegIFN and Rbv treatment,
5) pre-existing anemia due to hemoglobin disorders, 6) malignan-
cy. The study was approved by the IRB of the Department of
Medicine of the Ospedale Maggiore Policlinico of Milan.
Antiviral Treatment
All patients received a combination of TVR 750 mg every
8 hours, PegIFNa2a 180 mcg/week or PegIFNa2b 1.5 mcg/Kg/
week, and Rbv for 12 weeks, followed by an additional 36 weeks of
PegIFN and Rbv alone. Treatment duration followed the EMA
approved TVR label. Telaprevir was administrated every 8 hours
with food. Rbv was administrated according to PegIFN label. All
patients were evaluated for safety and tolerance of therapy every 2
weeks during the TVR treatment period. PegIFNa2a was reduced
to 135 mcg and PegIFNa2b to 1,0 mcg/Kg per week in patients
with ,0,756109/L neutrophils at two consecutive tests whereas it
was interrupted in patients with ,0,506109/L. The same dose
reductions were applied if platelets were under 50,000 cells/mm3
with PegIFN being discontinued when reaching the 25,000 cells/
mm3 threshold.
Therapy was discontinued if HCV-RNA was .1000 IU/ml at
week 4 or 12, if HCV-RNA was detectable at week 24 and in case
of virological breakthrough (any detectable HCV RNA after
achieving undetectable levels).
Menagement of anemia
Complete blood count was checked every 2 weeks for the first
12 weeks of therapy, and then every 4 weeks. Anemia severity was
defined as grade 1 when Hb values were between 10–10,9 g/dl or
Hb decline was 2,5–3,4 g/dl from baseline; grade 2 anemia was
Hb values between 9,0–9,9 g/dl or Hb decline of 3,5–4,4 g/dl
from baseline, grade 3 anemia was Hb between 7,0–8,9 g/dl or
Hb decline.4,5 from baseline; grade 4 for was Hb,7,0 g/dl.
Rbv dose reductions (RbvDR), growth factors and blood
transfusions were allowed for the management of anemia. The
management strategy was at the discretion of the investigator,
however Rbv dose reductions and/or Erythropoietin alfa 20,000
to 40,000 IU/week administration were allowed to manage
anemia only if Hb levels were less than 10 g/dL. Blood
transfusions were allowed only if Hb was ,8,5 g/dl. If Rbv had
to be discontinued, TVR was discontinued at the same time and
the decision to continue PegIFN monotherapy or discontinue
treatment was at the discretion of the investigator.
Measurements
Serum HCV-RNA was assessed by the Abbott RT-PCR assay
with a detection limit of 12 IU/ml at weeks 2, 4, 8 and 12. Liver
biopsies were performed with a 16 gauge Tru-Cut needle (Uro-
Cut 16G, TSK, Tokyo, Japan) and read by a single pathologist
who was unaware of patient’s identity and treatment regimen.
Liver biopsies fibrosis stage was assessed according to the
METAVIR scoring system [11]: F3 numerous septa without
cirrhosis, F4 cirrhosis.
Liver stiffness measurement (LSM) was performed by fibroscan
as already described [12]. LSM was expressed in kiloPascal (kPa)
as the median value of the successful measurements. Only LSM
data with at least ten successful measurements, success rate higher
than 60%, and inter quartile ratio (IQR) inferior to 30%, were
considered reliable [13]. LSM were performed by officially trained
operators.
Genetic testing
Genotyping of the ITPA polymorphisms rs1127354 and
rs7270101 was performed using the Allelic Inhibition of Displace-
ment Activity (AIDA) assay [14]. For the ITPA rs1127354
polymorphism heterozygotes (CA) or homozygotes (AA) of the
minor allele (A) are described as having the ITPA minor allele,
whereas homozygotes for the major allele (CC) are described as
having the ITPA major allele.
Conversely for the ITPA rs7270101 polymorphism heterozy-
gotes (AC) or homozygotes (CC) of the minor allele (C) are
described as having the ITPA minor allele, whereas homozygotes
for the major allele (AA) are described as having the ITPA major
allele. ITPA deficiency phenotypes were then classified according
to the degree of predicted ITPA deficiency (0–3: no ITPA
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deficiency, mild, moderate or severe deficiency), based on the
combination of bi-allelic polymorphisms (table 1).
Statistical analysis
Statistical analyses were conducted using the Mann–Whitney U
test or the Student t test for continuous variables and the x2 or
Fisher exact probability test for categorical data. A probability
value of p,0,05 was considered statistically significant. All
variables with statistical significance at the univariate analaysis
were included in the final model and odds ratios (OR) and
corresponding 95% confidence interval (95% CI) were computed.
Calculations were done with Stata 10.0 statistical package.
Results
Patients
During the enrolment period 69 patients met the inclusion
criteria and were analyzed in the present study. Patients
characteristics are shown in table 2. The mean age was 57 years
old, with 46% older than 60 years. Female patients represented
33% of the overall cohort. All patients had advanced fibrosis and
51 (74%) had cirrhosis, in 28 cases defined by liver biopsy and in
the remaining 23 cases by TE. No patient had pre-treatment
anemia or impaired baseline kidney function, the mean estimated
glomerular filtration rate was 93 ml/min/1,73 m2 by the MDRD
equation. HCV genotype 1b was the most frequent subtype being
found in 83% of the patients. Only 9 (13%) patients were
treatment naı¨ve, the remaining 60 treatment experienced patients
were classified as relapsers (38%), partial responders (14%), null
responders (32%) or virological breakthroughs (3%) to a previous
PR treatment. 48 patients (70%) had no ITPA deficiency, the
remaining 21 (30%) showed varying degrees of deficiency: mild
ITPA deficiency was found in 12 (17%) and moderate deficiency
was found in 9 patients (13%). None of the enrolled patients
showed severe ITPA deficiency. Epidemiological, clinical and
virological features did not differ between ITPA deficient and non
deficient patients (data not shown).
ITPA deficiency and severity of anemia
57 patients (83%) completed the 12 weeks of PR+TVR
treatment. The reasons from premature treatment discontinuation
in the remaining 12 patients were the following: virological
stopping rule in 2 cases (3%), severe anemia in 5 (7%),
Hepatocellular carcinoma (HCC) in 1 patient (1%) and treatment
related side effects other than anemia in 4 cases (6%). Treatment
discontinuation rates were 21% (10/48) of non ITPA deficient
patients, in 8% (1/12) of mild and 11% (1/9) of moderate deficient
patients (p = 0.3). Premature discontinuation for severe anemia
occurred in 8% of non ITPA deficient patients (4/48), 8% of mild
deficient patients (1/12) and 0% of moderate deficient patients
(p = 1).
Any grade anemia was observed in 68 (98%) patients: 2 (3%)
patients developed grade 1 anemia, 14 (20%) developed grade 2
anemia, 51 (74%) developed grade 3 anemia and 1 (1%) developed
grade 4 anemia. Grade 3–4 anemia developed in 81% of non
ITPA deficient versus 67% of mild ITPA deficient patients and
55% of moderate ITPA deficient patients (p = 0.1). The only factor
associated with development of grade 3–4 anemia was age .60
years (OR 5,88; 95% CI: 1,50–22,96).
The mean Hb values during the first 16 weeks of treatment
stratified by ITPA deficiency are shown in figure 1. The mean
decline in Hb values after 2 and 4 weeks of treatment was
significantly more pronounced in patients without ITPA deficiency
than in mild ITPA deficient patients and moderate ITPA deficient
patients (week 2 Hb decline: 1,99 g/dl vs 1,26 g/dl vs 0,37 g/dl,
Table 1. Degrees of ITPA deficiency according to rs1127354/rs7270101 genotypes combinations (0–3: no ITPA deficiency, mild,
moderate or severe deficiency).
rs1127354 rs7270101 Predicted ITPA activity Predicted ITPA deficiency
Wild-type (C/C) Wild-type (A/A) 100% 0
Wild-type (C/C) Heterozygosity (A/C) 60% 1
Heterozygosity (C/A) Wild-type (A/A) 30% 2
Wild-type (C/C) Homozygosity (C/C) 30% 2
Heterozygosity (C/A) Heterozygosity (A/C) 10% 3
Homozygosity (A/A) Wild-type (A/A) ,5% 3
doi:10.1371/journal.pone.0095881.t001
Table 2. Patients characteristics.
Feature Overall
Female sex, n(%) 23 (33%)
Age years, mean (range) 57 (35–69)
Cirrhosis, n(%) 51 (74%)
eGFR, mean ml/min 93,2
HCV 1b genotype, n(%) 57 (83%)
HCV-RNA.600.000 IU/ml, n(%) 42 (61%)
Hb g/dL, mean (range) 15,1 (10,8–18,0)
Male 15,6 (12,0–18,0)
Female 14,2 (10,8–15,9)
Previous treatment status, n(%)
Naive 9 (13%)
Relapse 26 (38%)
Partial Response 10 (14%)
Null response 22 (32%)
Breakthrough 2 (3%)
Grade of ITPA deficiency, n(%)
No deficiency 48 (70%)
Mild deficiency 12 (17%)
Moderate deficiency 9 (13%)
doi:10.1371/journal.pone.0095881.t002
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p = 0,0006; week 4 Hb decline: 3,85 g/dl vs 3,07 g/dl vs 1,67 g/
dl, p,0,0001). This resulted in significantly lower mean Hb values
after 4 weeks of PR+TVR in patients without ITPA deficiency
compared to patients with mild or moderate ITPA deficiency
(week 4 Hb: 11,4 g/dl vs 12,4 g/dl, p = 0,01).
However due to a sharper decline in Hb values at week 8 and 12
of PR+TVR in ITPA deficient patients, the week 8 and 12 levels of
Hb did not differ across ITPA deficient categories (figure 1).
At the time of analysis, 42 and 32 patients respectively have
undergone blood tests at week 16 and 20 of therapy, i.e 4 and 8
weeks after discontinuation of TVR. Hb levels at these time points
did not significantly differ between ITPA deficient and non
deficient patients (figure 1).
ITPA deficiency and management of anemia
During the first 12 weeks of PR+TVR, 42 patients (60%)
required RbvDR. RbvDR rates were not associated with ITPA
deficiency as they occurred in 60% of ITPA non deficient patients,
in 58% mild ITPA deficient patients and 67% moderate ITPA
deficient patients (table 3). RbvDR during the first 4 weeks of
treatment was requested in 17 patients (40%) and it was more
frequent in non ITPA deficient patients (14/48) as compared to
patients with any grade ITPA deficiency (3/21), however this
difference was not statistically significant (29% vs 14%, p = 0.2).
Erythropoietin use was allowed to manage anemia in this study
and was overall required in 43 (62%) patients. ITPA deficiency did
not impact the frequency of Erythropoietin use: 65% in the no
ITPA deficiency group, 58% in the mild ITPA deficiency group
and 56% in the moderate ITPA deficiency setting. Blood
transfusions were deemed necessary by the investigator in 18
patients (26%): 27% had no ITPA deficiency, 17% had mild ITPA
deficiency and 33% had moderate ITPA deficiency. ITPA
deficiency therefore was not associated with RbvDR, erythropoi-
etin support or need for blood transfusions (table 3).
We analyzed several other baseline factors that could impact on
anemia management such as female gender, age, cirrhosis,
baseline Hb values and eGFR. By multivariate analysis RbvDR
was associated with female sex (OR:18,5; 95% CI 2,06–166,6),
Epo use with age .60 years (OR: 4,42; 95% CI: 1,25–15,6), while
blood transfusions were associated with either female sex
(OR:4,86; 95% CI 1,22–19,22) and baseline Hb values (OR
0,46: 95% CI: 0,25–0,87)
ITPA and virological response rates
Virological response rates during the first 12 weeks of therapy
are resumed in table 4. No impact of ITPA deficiency severity was
seen on rates of HCV RNA undetectability at week 4, 8 or 12.
Discussion
Development of severe early anemia during treatment with
PR+TVR has been reportedly shown as one of the major clinical
issues in patients with advanced fibrosis/cirrhosis. In real life
studies focused on this subgroup of patients, grade 3–4 anemia
developed in one out of three such patients, requiring Erythro-
poietin support or blood transfusions in up to 54% and 16% of
patients, respectively [3–4]. Our cohort of Caucasian patients with
advanced fibrosis/cirrhosis confirms these figures, showing that
development of early anemia was the main reason for early
discontinuation of PR+TVR.
By ITPA genotyping at baseline we were able to show that
ITPA polymorphisms could anticipate the severity of Hb decline
in the first 4 weeks of PR+TVR, as patients with moderate
deficiency were those with a lesser decline in mean hemoglobin
values at week 2 and 4 of triple therapy. However, this benefit was
lost in the following 8 weeks of triple therapy as the week 12 Hb
values were not different across ITPA deficient subgroups. The
same finding has been reported by two studies conducted in
Japanese patients receiving PR+TVR, which enrolled also patients
with mild fibrosis [9–10]. Although it is hard to explain why ITPA
deficiency protects from development of anemia only in the early
weeks of PR+TVR treatment, this might be the direct conse-
quence of the increased plasma Rbv levels that have been reported
to occur after 4 weeks of treatment with TVR. In a small study
comparing plasma levels of Rbv in 16 patients who received PR
and 5 patients who received PR+TVR, intracellular Rbv levels
were shown to be similar among the two groups of patients until
week 4 of therapy and then increase significantly in the PR+TVR
group compared to the PR group [15]. Another small study
reported higher Rbv plasma concentrations after 8 weeks of
treatment in 9 patients treated with TVR compared to 187
patients who received PR [16].
In theory this findings fit well with the loss of protection from
ITPA deficiency towards on treatment anemia that we observed
following 4 weeks of PR+TVR therapy. ITPA deficiency is
thought to protect against Rbv induced anemia, by protecting
against ATP depletion in the erythrocyte. Indeed Rbv has been
shown to cause anemia through direct suppression of erythropoi-
Figure 1. Mean hemoglobin values during treatment with PR+TVR stratified by ITPA deficiency.
doi:10.1371/journal.pone.0095881.g001
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esis as well as due to depletion of GTP which in turn reduces the
levels of ATP in erythrocytes [17]. Intracellular ITP, which
accumulates in ITPA deficient patients can substitute for
erythrocyte GTP, thus allowing physiological levels of ATP in
erythrocytes [18]. This explains why at standard doses of Rbv,
patients with ITPA deficiency show less severe anemia when
treated with PR, however, whether this mechanism still protects
from anemia at higher plasmatic Rbv concentrations needs to be
demonstrated. High intracellular levels of Rbv in the second and
third month of PR/TVR could explain why Rbv reductions have
been shown not to impact negatively on SVR rates [19].
Whatever the precise mechanisms by which ITPA deficiency
fails to protect from PR+TVR severe anemia may be, our study
shows that estimated ITPA deficiency grade through genotyping of
rs1127354 and rs7270101 at baseline is of limited clinical utility.
Indeed, ITPA deficiency was not associated with the management
strategy for anemia, as Erythropoietin use, RbvDR and blood
transfusion necessity were similar between ITPA groups. This is in
our opinion a significant finding as not only it conflicts with what
reported for PR therapy, where ITPA deficiency was associated
with the need to use erythropoietin and blood transfusions, but
also does not support routine genetic testing of ITPA variants
before starting PR+TVR [8].
We are aware that our study is not free of limitations, as it was
retrospective and conducted on a relatively small sample size of
Caucasian patients. The limited sample size of our study was the
direct consequence of our choice to stop enrolment after a 6
month period, rather than to conduct an analysis on a predefined
number of patients. The rationale behind this was to allow our
study to enter the evolving HCV treatment field as quickly as
possible, hence making it easily and rapidly accessible for
everyday’s clinical practice. Still we are aware that this somewhat
limits the overall impact of our findings as we cannot completely
rule out a Type II error in our analysis, the power of our study to
assess the role of ITPA variants on Hb decline was 90.8%. We also
acknowledge that, although the anemia management strategy was
homogenous between centres, ultimately the choice to reduce Rbv
dose, administer Erythropoietin or blood transfuse was at the
discretion of the investigator. This was the consequence of the
general lack of consensus on how to manage anemia during TVR
treatment. Several retrospective studies have shown that RbvDR
can be effective in improving anemia without compromising SVR
rates, still at this time there are no consensus guidelines on the
optimal timing of RbvDR as well as the lowest effective Rbv dose,
especially in patients with advanced fibrosis receiving TVR [19–
20–21]. Moreover, although RbvDR are considered by the experts
to be the best strategy to manage severe anemia during TVR, in
some cases severe anemia is so quick to develop that erythropoietin
and blood transfusion are necessary to improve the patients quality
of life while continuing PR+TVR treatment. Lastly we do not
think that our study findings can be translated to the other
currently available NS3 protease inhibitor BOC, which also causes
anemia through mechanisms that are still poorly understood [21–
22].
Still all these limitations notwithstanding, we think that our
study has clinical relevance as it demonstrates, in a time of limited
economical resources, that the clinical utility of ITPA genotyping
in HCV-1 patients receiving PR+TVR is limited at least in those
with advanced fibrosis/cirrhosis, as it does not predict manage-
ment of anemia nor development of grade 3 anemia during TVR
therapy. Although ITPA deficiency was associated with HB
decline during the first 2–4 weeks of therapy, from a clinical
standpoint we think this does not support routine ITPA genetic
testing in patients candidate to TVR treatment.
Author Contributions
Conceived and designed the experiments: AA MGR MC. Performed the
experiments: E. Galmozzi RS. Analyzed the data: AA E. Grassi RD ED.
Contributed reagents/materials/analysis tools: MGR DC. Wrote the
paper: AA E. Grassi MC.







Mean D Hb week 4 g/dL 3,85 3,07 1,67 ,0,0001
RbvDR, n(%) 29 (60%) 7 (58%) 6 (67%) 1*
Erythropoietin use, n(%) 31 (65%) 7 (58%) 5 (56%) 0.6*
Transfusion, n(%) 13 (27%) 2 (17%) 3 (33%) 1*
Treatment discontinuation within week 12, n(%) 10 (21%) 1 (8%) 1 (11%) 0.3*
Discontinuation for severe anemia, n(%) 4 (8%) 1 (8%) 0 (0%) 1*
*No ITPA deficiency vs any ITPA deficiency.
doi:10.1371/journal.pone.0095881.t003
Table 4. Rates of HCV RNA undetectability during treatment stratified by ITPA deficiency.
No ITPA Deficiency (n=48) Mild ITPA Deficiency (n =12) Moderate ITPA deficiency (n=9) P*
Undetectable HCV-RNA
Week 4, n(%) 21 (44%) 6 (50%) 3 (33%) 0,79
Week 8, n(%) 39 (81%) 10 (83%) 9 (100%) 0,48
Week 12, n(%) 38 (79%) 10 (83%) 9 (100%) 0,32
*No ITPA deficiency versus any ITPA deficiency.
doi:10.1371/journal.pone.0095881.t004
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